MRK - Merck & Co., Inc.
85.27 0.00 (0.00%)
After hours: 4:30PM EST
| Previous Close | 84.65 |
| Open | 84.53 |
| Bid | 85.18 x 1100 |
| Ask | 85.22 x 800 |
| Day's Range | 84.45 - 85.48 |
| 52 Week Range | 70.89 - 87.35 |
| Volume | 5,475,927 |
| Avg. Volume | 8,118,787 |
| Market Cap | 217.096B |
| Beta (3Y Monthly) | 0.55 |
| PE Ratio (TTM) | 23.83 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.20 (2.60%) |
| Ex-Dividend Date | 2019-09-13 |
| 1y Target Est | N/A |
- MarketWatch
Your three-stock survival kit for 2020 — packed by Nuveen’s top stock-market strategist
Our call of the day from Nuveen’s equity strategists says investors need to brace for a coming year that won’t top the 20%-plus gains we’ve been seeing. The key to survival are these three stocks.
- Zacks
Medicines Company Up on Rumors of Potential Buyout by Novartis
The Medicines Company (MDCO) is rumored to attract acquisition offers after impressive data readouts from three pivotal studies on PCSK9 inhibitor candidate, inclisiran.
- American City Business Journals
Keytruda researcher launches cancer-focused Werewolf Therapeutics with $56M
The company is founded and led by MPM Capital partner and cancer researcher Daniel Hicklin, who oversaw the development of Merck’s immuno-oncology drug Keytruda and other cancer products.
- MarketWatch
Merck raises quarterly dividend, to yield more than peers and the S&P 500
Shares of Merck & Co. Inc. were up 0.3% in midday trading Tuesday, after the health care company said it will raise its quarterly dividend by 11%. The company will pay a dividend of 61 cents a share, up from 55 cents a share, on Jan. 8 to shareholders or record on Dec. 16. Based on the current stock price, the new annual dividend rate would imply a dividend yield of 2.89%, compared with the yield for the SPDR Health Care Select Sector ETF of 1.54% and the implied yield for the S&P 500 of 1.90%. Merck's stock has slipped 2.1% over the past three months, while the health care ETF has gained 6.7%, the S&P 500 has tacked on 6.7% and the Dow Jones Industrial Average has advanced 6.9%.
- GuruFocus.com
Drug Legislation Likely to Dry Up Biotech Funding
Industry executives claim the proposed law will inhibit the development of life-saving medications Continue reading...
- Zacks
Merck's Heart Failure Candidate Meets Goal in Phase III Study
Merck (MRK) and German partner Bayer's vericiguat reduces the risk of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure.
- Zacks
Novo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies
Novo Nordisk (NVO) inks deal with Dicerna Pharmaceuticals to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases.
- American City Business Journals
Gluware teams with Juniper to diagnose complex wireless networks
Sacramento’s Gluware Inc. is helping Juniper Network Inc.’s Mist Systems to diagnose and find problems in complex wireless networks.
- Zacks
Medicines Company Posts Full Inclisiran Data From ASCVD Study
The Medicines Company (MDCO) reports detailed data from the phase III ORION-10 study on its lead candidate inclisiran to treat patients with ASCVD.
- Barrons.com
Beyond Meat Is Shaking Up the Meat Industry. Animal-Health Stocks Could Take a Hit, Too.
Wall Street has high hopes for the alternative-meat industry. If the world does end up eating less animal-based protein in the future, other industries—besides just meat producers—will be affected.
- Zacks
Bristol-Myers Gets FTC Clearance for Celgene Acquisition
Bristol-Myers (BMY) obtains FTC permission for the Celgene acquisition and will divest Otezla to Amgen.
- Zacks
Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us take a look at the reasons for the same.
- Barrons.com
How to Generate Retirement Income With a Total Return Strategy
A look at how portfolio assets can be periodically rebalanced (from better-performing asset classes to underperformers, for example) and occasionally sold to supplement income for retirees.
- Zacks
5 Blue-Chip Stocks to Buy as Dow Breezes Past 28,000
We highlight blue-chip companies slated to gain in the near term as they have large market capitalization, strong balance sheet and solid cash flow.
- Bloomberg
Thiel Marks Palantir’s Asia Push with $150 Million Japan Venture
(Bloomberg) -- In a rare show of public support, Palantir Technologies Inc.’s co-founder and chairman Peter Thiel pitched the power of the data-mining company during a splashy Tokyo event marking its formal entry into Asia.The billionaire entrepreneur was in Japan Monday to unveil a $150 million, 50-50 joint venture with local financial services firm Sompo Holdings Inc., Palantir Technologies Japan Co. The new company will target government and public sector customers, emphasizing health and cybersecurity initially. Like IBM Corp. and other providers, Palantir’s software pulls together a range of data provided by its customers, mining it for patterns and displaying connections in easy-to-read spiderweb-like graphics that might otherwise get overlooked.“We can learn a lot from Japan, that some of the challenges that Japan has with its aging population are the ones all countries of the West are going to have in the years ahead,” Thiel said at a briefing in Tokyo. “We hoped this can be a two-way exchange.”The push into Asia comes at a critical time for the 15-year-old company. Despite having long-term, billion-dollar contracts with BP Plc., Merck KGaA and others in more than a dozen countries worldwide, Palantir has never turned an annual profit. Under the leadership of Thiel and the management of Chief Executive Officer Alex Karp, Palantir has long emphasized engineering over sales and revenue, a focus that has shifted only this year.The company has not set a date for an initial public offering and continues to explore raising additional funding from private investors. Palantir spokeswoman Lisa Gordon told Bloomberg there are no formal conversations underway and disputed reports that Palantir is considering a deal with Softbank Group Corp. or that the company is seeking as much as $3 billion in funding at a $30 billion valuation.Valuation is a touchy subject for the Silicon Valley company. Although private investors valued Palantir in 2015 at more than $20 billion, aggressive markdowns by mutual funds and an uncertain IPO timeline have taken a toll. Palantir’s valuation has continued to tumble, with shares trading around $5 a share during the past month, according to data from secondary markets.Palantir is very close to breaking even and will end 2019 either slightly in the black or slightly in the red, Thiel said at the briefing. The company will be “significantly in the black” next year, he added.“The judgment call Palantir has made, as have many other companies in Silicon Valley post 2000, is it is often much better to build businesses in private,” Thiel said. “There is some day in the future when Palantir will go public, but we will try to stay private as long as possible.”Palantir’s public image has taken a beating in recent years. It’s attracted scrutiny from privacy advocates and protesters disturbed by the way Palantir’s software has been used by state and local law enforcement in the U.S., as well as by federal agencies like the Department of Homeland Security while implementing the controversial family separation policy at the U.S. Mexican border.Thiel himself has been a lightning rod for criticism, having helped the election of U.S. President Donald Trump in 2016, a divisive decision even within Palantir. That critique could intensify given he has pledged to support Trump’s 2020 re-election.“I envision supporting President Trump over his likely Democratic nominees,” Thiel said in Tokyo, adding he will determine the exact nature of his support as elections approach.(Updates with comments from news briefing from the third paragraph.)To contact the reporters on this story: Pavel Alpeyev in Tokyo at palpeyev@bloomberg.net;Lizette Chapman in San Francisco at lchapman19@bloomberg.netTo contact the editors responsible for this story: Edwin Chan at echan273@bloomberg.net, Vlad SavovFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- Insider Monkey
Hedge Funds Open Kimono: 5 Best Healthcare Stocks To Buy
We believe one of the best tools for ordinary investors who are on the hunt for new ideas is 13F filings. Once every quarter hedge funds with at least $100 million in total positions in publicly traded US stocks/options are required to open the kimono and disclose the number of shares and the total value of […]
- Zacks
AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status
The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.
- Zacks
Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates
Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.
- Zacks
4 Big Drugmakers to Bet on After a Great Earnings Season
Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.
- GuruFocus.com
Livongo Bounces Back After Revenue Guidance Boost
Analysts set average 12-month target more than 70% above current price Continue reading...
- MarketWatch
Cisco, Merck share losses lead Dow's nearly 75-point drop
DOW UPDATE The Dow Jones Industrial Average is trading down Thursday morning with shares of Cisco and Merck seeing the biggest drops for the blue-chip average. Shares of Cisco (CSCO) and Merck (MRK) have contributed to the blue-chip gauge's intraday decline, as the Dow (DJIA) was most recently trading 70 points (0.
- Zacks
Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss
Celldex (CLDX) reports mixed third-quarter results. Its revenues fall on reduced collaboration and contract revenues.
- Zacks
FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes
Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.
- MarketWatch
Merck posts higher profit and revenue as it lifts sales forecast
Merck said it now expects to report overall sales of between EUR15.7 billion and EUR16.3 billion for 2019, from between EUR15.3 billion and EUR15.9 billion.
- Bloomberg
Merck KGaA CFO on M&A Hiatus, Third-Quarter Earnings
Nov.15 -- Marcus Kuhnert, chief financial officer of Merck KGaA, said the company will focus on integrating Versum Materials before it starts looking for a new takeover target. He spoke Nov. 14 on "Bloomberg Markets: European Open" after the firm posted third-quarter earnings.
